BCYC - Bicycle Therapeutics plummets as price target cut to $75 by Needham

Bicycle Therapeutics (BCYC -11.2%) has its price objective reduced by equities research analysts at Needham & Co. from $85 to $75 in a research note issued. The firm presently has a “Buy” rating on the stock. Needham & Co.’s target price would suggest a potential upside of 160.33% from the company’s current price. Since the start of 2022, Bicycle Therapeutics shares fell by 57% but over a period of one year shares were down around 5.2%. Wall Street analysts stands with a Buy rating on the stock and Seeking Alpha Quant System also says to Strong Buy.

For further details see:

Bicycle Therapeutics plummets as price target cut to $75 by Needham